Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Wendy Donaugh

Nurse Practitioner, Family Billings, MT Nurse Practitioner

NPI 1336523836 CMS profile 4211644

2409 Arnold Ln Ste 9, Billings, MT 59102

Open in the dashboard

General payments

$3,006

169 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Wendy Donaugh of Billings, MT is reported in the CMS Open Payments database as having received $3,006 across 169 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $633 38
2024 General $603 32
2023 General $533 32
2022 General $686 35
2021 General $551 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Wendy Donaugh
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Wendy Donaugh were reported at $633. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Wendy Donaugh Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $551 $124 $35–$379 $132
2022 $686 $141 $44–$430 $149
2023 $533 $154 $49–$476 $160
2024 $603 $165 $51–$504 $164
2025 $633 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Amgen Inc. $510 35 payments
  2. AbbVie, Inc. $408 25 payments
  3. UCB, Inc. $335 18 payments
  4. Janssen Biotech, Inc. $273 13 payments
  5. Novartis Pharmaceuticals Corporation $189 12 payments
  6. ANI Pharmaceuticals, Inc. $181 9 payments
  7. Horizon Therapeutics plc $176 5 payments
  8. GlaxoSmithKline, LLC. $159 11 payments
  9. AstraZeneca Pharmaceuticals LP $142 8 payments
  10. Alexion Pharmaceuticals, Inc. $110 5 payments
  11. Other $523 28 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,972 167 payments
  2. Education $35 2 payments
Products named General payments · program years 2021–2025
  1. RINVOQ $373 24 payments
  2. Cimzia $301 16 payments
  3. Enbrel $299 21 payments
  4. TREMFYA $232 11 payments
  5. Otezla $214 16 payments
  6. KRYSTEXXA $176 5 payments
  7. BENLYSTA $159 11 payments
  8. PURIFIED CORTROPHIN GEL $157 8 payments
  9. SAPHNELO $142 8 payments
  10. COSENTYX $118 8 payments
  11. Other $1,266 65 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

565

Median for Nurse Practitioner: 389

Drug cost

$1,327,942

Median for Nurse Practitioner: $21,885

Branded share of claims

23.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cortrophin Corticotropin Brand 17 $1,225,185
Rinvoq Upadacitinib Brand 14 $92,272
Hydroxychloroquine Sulfate Generic 93 $3,771
Methotrexate Methotrexate Sodium Brand 102 $1,671
Pilocarpine Hcl Generic 20 $1,592
Leflunomide Generic 17 $1,427
Meloxicam Generic 63 $425
Prednisone Generic 90 $422
Celecoxib Generic 18 $400
Cyclobenzaprine Hcl Generic 38 $226

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$285,981

Of which drugs: $257,000

Medicare patients

98

Average age 70

Services billed

38,578

77 women, 21 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 53%
Osteoporosis 33%
Depression 31%
Chronic kidney disease 20%
COPD 19%
Diabetes 17%
Ischemic heart disease 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, golimumab, 1 mg, for intravenous use J1602 Office 13 8,950 $80,262
Injection, denosumab, 1 mg J0897 Office 13 1,500 $30,936

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Enbrel
  • Amgen Inc. $93
$93 — —
SAPHNELO
  • AstraZeneca Pharmaceuticals LP $92
$92 — —
PURIFIED CORTROPHIN GEL
  • ANI Pharmaceuticals, Inc. $88
$88 — —
TREMFYA
  • Janssen Biotech, Inc. $83
$83 — —
ACTHAR
  • Mallinckrodt Hospital Products Inc. $57
$57 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

169 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Montana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record